BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 19808967)

  • 1. Runt-related transcription factor RUNX3 is a target of MDM2-mediated ubiquitination.
    Chi XZ; Kim J; Lee YH; Lee JW; Lee KS; Wee H; Kim WJ; Park WY; Oh BC; Stein GS; Ito Y; van Wijnen AJ; Bae SC
    Cancer Res; 2009 Oct; 69(20):8111-9. PubMed ID: 19808967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line.
    Vaskivuo L; Rysä J; Koivuperä J; Myllynen P; Vaskivuo T; Chvalova K; Serpi R; Savolainen ER; Puistola U; Vähäkangas K
    Toxicol Appl Pharmacol; 2006 Oct; 216(1):89-97. PubMed ID: 16797627
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Lee YS; Lee JY; Song SH; Kim DM; Lee JW; Chi XZ; Ito Y; Bae SC
    Mol Cells; 2020 Oct; 43(10):889-897. PubMed ID: 33115981
    [No Abstract]   [Full Text] [Related]  

  • 4. Dynamics in the p53-Mdm2 ubiquitination pathway.
    Brooks CL; Gu W
    Cell Cycle; 2004 Jul; 3(7):895-9. PubMed ID: 15254415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of CCDC69 activates p14
    Cui L; Zhou F; Chen C; Wang CC
    J Ovarian Res; 2019 Jan; 12(1):4. PubMed ID: 30651135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UBTD1 induces cellular senescence through an UBTD1-Mdm2/p53 positive feedback loop.
    Zhang XW; Wang XF; Ni SJ; Qin W; Zhao LQ; Hua RX; Lu YW; Li J; Dimri GP; Guo WJ
    J Pathol; 2015 Mar; 235(4):656-67. PubMed ID: 25382750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of p53 C-terminal acetylation by mdm2, p14ARF, and cytoplasmic SirT2.
    van Leeuwen IM; Higgins M; Campbell J; McCarthy AR; Sachweh MC; Navarro AM; Laín S
    Mol Cancer Ther; 2013 Apr; 12(4):471-80. PubMed ID: 23416275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.
    Midgley CA; Desterro JM; Saville MK; Howard S; Sparks A; Hay RT; Lane DP
    Oncogene; 2000 May; 19(19):2312-23. PubMed ID: 10822382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancer.
    Amir S; Ma AH; Shi XB; Xue L; Kung HJ; Devere White RW
    PLoS One; 2013; 8(4):e61064. PubMed ID: 23585871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression of proteins in p53 (p14ARF-mdm2-p53-p21WAF/CIP1) pathway and their significance in exocrine pancreatic carcinoma].
    Yu GZ; Zhu MH; Ni CR; Li FM; Zheng JM; Gong ZJ
    Zhonghua Bing Li Xue Za Zhi; 2004 Apr; 33(2):130-4. PubMed ID: 15132849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mdm2 mutant defective in binding p300 promotes ubiquitination but not degradation of p53: evidence for the role of p300 in integrating ubiquitination and proteolysis.
    Zhu Q; Yao J; Wani G; Wani MA; Wani AA
    J Biol Chem; 2001 Aug; 276(32):29695-701. PubMed ID: 11340074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of p53 ubiquitination and nuclear export by MDM2 and ARF.
    Zhang Y; Xiong Y
    Cell Growth Differ; 2001 Apr; 12(4):175-86. PubMed ID: 11331246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epithelial cell-derived periostin functions as a tumor suppressor in gastric cancer through stabilizing p53 and E-cadherin proteins via the Rb/E2F1/p14ARF/Mdm2 signaling pathway.
    Lv H; Liu R; Fu J; Yang Q; Shi J; Chen P; Ji M; Shi B; Hou P
    Cell Cycle; 2014; 13(18):2962-74. PubMed ID: 25486483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14(ARF)-MDM2-p53 axis.
    Van Maerken T; Vandesompele J; Rihani A; De Paepe A; Speleman F
    Cell Death Differ; 2009 Dec; 16(12):1563-72. PubMed ID: 19779493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low p14ARF expression in neuroblastoma cells is associated with repressed histone mark status, and enforced expression induces growth arrest and apoptosis.
    Dreidax D; Gogolin S; Schroeder C; Muth D; Brueckner LM; Hess EM; Zapatka M; Theißen J; Fischer M; Ehemann V; Schwab M; Savelyeva L; Westermann F
    Hum Mol Genet; 2013 May; 22(9):1735-45. PubMed ID: 23343716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MdmX inhibits ARF mediated Mdm2 sumoylation.
    Ghosh M; Weghorst K; Berberich SJ
    Cell Cycle; 2005 Apr; 4(4):604-8. PubMed ID: 15876864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRIAD1 inhibits MDM2-mediated p53 ubiquitination and degradation.
    Bae S; Jung JH; Kim K; An IS; Kim SY; Lee JH; Park IC; Jin YW; Lee SJ; An S
    FEBS Lett; 2012 Sep; 586(19):3057-63. PubMed ID: 22819825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor.
    Chen D; Kon N; Li M; Zhang W; Qin J; Gu W
    Cell; 2005 Jul; 121(7):1071-83. PubMed ID: 15989956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RUNX3 is oncogenic in natural killer/T-cell lymphoma and is transcriptionally regulated by MYC.
    Selvarajan V; Osato M; Nah GSS; Yan J; Chung TH; Voon DC; Ito Y; Ham MF; Salto-Tellez M; Shimizu N; Choo SN; Fan S; Chng WJ; Ng SB
    Leukemia; 2017 Oct; 31(10):2219-2227. PubMed ID: 28119527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Farnesoid X receptor functions in cervical cancer via the p14
    Huang X; Wang B; Shen H; Huang D; Shi G
    Mol Biol Rep; 2022 May; 49(5):3617-3625. PubMed ID: 35347542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.